New AIDS Drug Receives FDA Approval
WASHINGTON, DC-A new nucleotide analog has been passed by the US Food and Drug Administration (FDA) in an attempt to help the current list of anti-viral AIDS drugs.
Viread, manufactured by Gilead Sciences of Foster City, Calif., was created to help fight against the rapidly mutating virus that has managed to create a resistance to many current AIDS drugs. The once-a-day pill will be available by week's end. Side effects include moderate diarrhea, nausea, vomiting, and flatulence.
In clinical trials of the drug, AIDS patients were found to have significant reduction in the amount of HIV cells in their bloodstream.
Viread is also known as tenofovir disoproxil fumarate.
Information from www.sfgate.com
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
